Innovating Works

XENOPAT

Activa
EVEREST: Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics The EVEREST project is a pioneering consortium in Extracellular Vesicle (EVs) research, bringing together 22 institutions from 11 countries,...
2024-08-01 - 2028-12-31 | Financiado
PERSIST-SEQ: Building a reproducible single cell experimental workflow to capture tumour cell persistence XENOPAT participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by deve...
2021-06-28 - 2026-06-30 | Financiado
CRYSTAL3: Commercial Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular CNS Dysfunction... XENOPAT participó en un H2020: H2020-MSCA-RISE-2020 Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorect...
2020-10-02 - 2024-12-31 | Financiado
cONCReTE: DevelOpmeNt of Cancer RNA TherapEutics XENOPAT participó en un H2020: H2020-MSCA-RISE-2019 Non-codingRNAs (ncRNAs) represent a large class of molecules that in concert regulate the expression of genes involved in the key pathways g...
2020-03-02 - 2025-10-31 | Financiado
3D NEONET: Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics XENOPAT participó en un H2020: H2020-MSCA-RISE-2016 Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of...
2016-11-08 - 2022-06-30 | Financiado
EPIPHARM: Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary XENOPAT participó en un H2020: ERC-2016-PoC The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a...
2016-10-10 - 2018-07-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.